A Phase 1 interventional study of PF-06882961 and Placebo in Diabetes Mellitus, Type 2, sponsored by Pfizer. Completed at 1 site in China. Open to participants aged 20 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-10-01.
Sponsored by Pfizer · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 80 studies in Diabetes Mellitus, Type 2 by Pfizer — 2 open to participants now, 3 under way, 3 of them phase 3. Diabetes Mellitus, Type 2 · Pfizer.
Among the 80 studies in Diabetes Mellitus, Type 2 by Pfizer, this one is the 62nd largest by enrollment of the 79 interventional ones that give a count, is one of 3 that started in 2021, is one of 47 in phase 1, and was the 73rd registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →2 of the 80 studies in Diabetes Mellitus, Type 2 by Pfizer are open now, in 11 countries. Recruiting first, the newest first:
Pfizer · Sites in United States
Ages 18+
Pfizer · Sites in United States, Brazil, Canada and 8 more countries
Ages 18+
By country, each count listing its studies:
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 20 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
80 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 50 across the 79 interventional studies, 32 across the 1 observational. Of the 77 that completed or were terminated, 39 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
1 of the studies in Diabetes Mellitus, Type 2 by Pfizer that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07400653Phase 3PfizerA Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) | 2027-10-12 |
Add it to your calendar (.ics) → With an account.
Among the 80 studies in Diabetes Mellitus, Type 2 by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 1, randomized, double-blind (sponsor open), placebo controlled study in adult Chinese participants with T2DM who are receiving metformin as background antihyperglycemic medication.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be titrated up to 6 weeks of the 8-week dosing duration to reach desired dose level 120 mg
Drug: PF-06882961
Placebo
Drug: Placebo
Participants will be administered active doses, taking 3 tablets twice daily (BID) for 8 weeks except Day 1 (QD)
3 matching placebo tablets taken twice daily (BID) except Day 1 (QD)
Area Under the Concentration-Time Curve From Time 0 to 24 Hours (AUC24) of PF-06882961 10 mg Single Dose on Day 1
AUC24 is the area under the plasma concentration-time profile from time zero to the time 24 hours. The planned analysis was not considered reliable by the sponsor.
Time frame: Pre-dose, 1, 2, 4, 6, 8, 10, 12, 14, 24 hours post dose on Day 1
Maximum Observed Concentration (Cmax) of PF-06882961 10 mg Single Dose on Day 1
Cmax is the maximum observed plasma concentration over 24 hours. The planned analysis was not considered reliable by the sponsor.
Time frame: Pre-dose, 1, 2, 4, 6, 8, 10, 12, 14, 24 hours post dose on Day 1
AUC24 of PF-06882961 in Participants Received 40 mg BID, 80 mg BID, and 120 mg BID PF-06882961
AUC24 was measured on Day 21, 35, and 56 for dose 40 mg BID, 80 mg BID, and 120 mg BID, respectively. The planned analysis was not considered reliable by the sponsor.
Time frame: Pre-dose, 1, 2, 4, 6, 8, 10, 12, 14, 24 hours post dose on Day 21 (40 mg BID), 35 (80 mg BID), and 56 (120 mg BID)
Maximum Observed Concentration, Steady State (Cmax,ss) of PF-06882961 in Participants Received 40 mg BID, 80 mg BID, and 120 mg BID PF-06882961
Cmax,ss was measured on Day 21, 35, and 56 for dose 40 mg BID, 80 mg BID, and 120 mg BID, respectively. The planned analysis was not considered reliable by the sponsor.
Time frame: Pre-dose, 1, 2, 4, 6, 8, 10, 12, 14, 24 hours post dose on Day 21 (40 mg BID), 35 (80 mg BID), and 56 (120 mg BID)
Number of Participants With Clinically Significant Change From Baseline in Vital Signs
Supine blood pressure and pulse rate were measured with the participant's arm supported at the level of the heart and recorded to the nearest mmHg after approximately 5 minutes of rest and maximum absolute values and maximum changes from baseline from time-matched baseline were evaluated at the investigator's discretion.
Time frame: Baseline up to 14 days after last dose (Day 70)
Number of Participants With Abnormal Electrocardiogram (ECG)
Standard 12-lead ECGs utilizing limb leads were collected using an ECG machine that automatically calculated the heart rate and measures PR, QT, and QT interval corrected for heart rate (QTc) and QRS complex.
Time frame: Baseline up to 14 days after last dose (Day 70)
Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs)
An AE was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An serious adverse event was defined as any untoward medical occurrence that,at any dose:resulted in death;was life-threatening;required inpatient hospitalization or prolongation of existing hospitalization;resulted in persistent disability/incapacity; was a congenital anomaly/birth defect;or other serious situations such as important medical events. The investigator was required to use clinical judgment to assess the potential relationship between investigational product and each AE, to define an treatment-related AE.
Time frame: Baseline up to 35 days after last dose (Day 91)
Number of Participants With Laboratory Abnormalities
Laboratory tests (including hematological, clinical chemistry, urinalysis tests) were reported and abnormality was determined at the investigator's discretion.
Time frame: Baseline up to 14 days after last dose (Day 70)
| Milestone | Placebo | PF-06882961 BID |
|---|---|---|
| Started | 5 | 15 |
| Discontinued | 0 | 0 |
| Completed | 5 | 15 |
| Not completed | 0 | 0 |
| Milestone | Placebo | PF-06882961 BID |
|---|---|---|
| Started | 5 | 15 |
| Received treatment | 5 | 15 |
| Completed | 5 | 15 |
| Not completed | 0 | 0 |
AUC24 is the area under the plasma concentration-time profile from time zero to the time 24 hours. The planned analysis was not considered reliable by the sponsor.
| nanogram*hour per milliter (ng*hr/mL) | PF-06882961 10 mg Single Dose |
|---|---|
| Area Under the Concentration-Time Curve From Time 0 to 24 Hours (AUC24) of PF-06882961 10 mg Single Dose on Day 1 | 287.4 ± 52 |
Cmax is the maximum observed plasma concentration over 24 hours. The planned analysis was not considered reliable by the sponsor.
| nanogram per milliter (ng/mL) | PF-06882961 BID |
|---|---|
| Maximum Observed Concentration (Cmax) of PF-06882961 10 mg Single Dose on Day 1 | 37.37 ± 39 |
Supine blood pressure and pulse rate were measured with the participant's arm supported at the level of the heart and recorded to the nearest mmHg after approximately 5 minutes of rest and maximum absolute values and maximum changes from baseline from time-matched baseline were evaluated at the investigator's discretion.
| Participants | Placebo | PF-06882961 BID |
|---|---|---|
| Supine systolic blood pressure (mmHg) change >=30 mm Hg increase | 1 | 3 |
| Supine systolic blood pressure (mmHg) change >=30 mm Hg decrease | 0 | 2 |
| Supine diastolic blood pressure (mmHg) change >=20 mm Hg increase | 1 | 6 |
| Supine diastolic blood pressure (mmHg) change >=20 mm Hg decrease | 0 | 1 |
| Supine pulse rate (beats per minute [bpm]) value >120 bpm | 0 | 1 |
Standard 12-lead ECGs utilizing limb leads were collected using an ECG machine that automatically calculated the heart rate and measures PR, QT, and QT interval corrected for heart rate (QTc) and QRS complex.
| Participants | Placebo | PF-06882961 BID |
|---|---|---|
| PR interval not otherwise specified (msec) %change >=50% | 0 | 1 |
| QTcF not otherwise specified (msec) 450 < Value <=480 | 1 | 1 |
An AE was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An serious adverse event was defined as any untoward medical occurrence that,at any dose:resulted in death;was life-threatening;required inpatient hospitalization or prolongation of existing hospitalization;resulted in persistent disability/incapacity; was a congenital anomaly/birth defect;or other serious situations such as important medical events. The investigator was required to use clinical judgment to assess the potential relationship between investigational product and each AE, to define an treatment-related AE.
| Participants | Placebo | PF-06882961 BID |
|---|---|---|
| Participants with non-serious AEs | 5 | 14 |
| Participants with serious adverse events | 0 | 0 |
Laboratory tests (including hematological, clinical chemistry, urinalysis tests) were reported and abnormality was determined at the investigator's discretion.
| Participants | Placebo | PF-06882961 BID |
|---|---|---|
| Hematology - Neutrophils (10^3/mm3) >1.2xupper limit of norma (ULN) | 0 | 1 |
| Hematology - Basophils (10^3/mm3) >1.2xULN | 0 | 1 |
| Chemistry - Urate (mg/dL) >1.2xULN | 0 | 4 |
| Chemistry - high-density lipoprotein cholesterol (mg/dL) <0.8xlower limit of normal (LLN) | 2 | 1 |
| Chemistry - Triglycerides (mg/dL) >1.3xULN | 0 | 3 |
| Chemistry - Thyrotropin (uIU/mL) <0.8xLLN | 0 | 1 |
| Chemistry - Bile Acid (umol/L) >1.0xULN | 0 | 1 |
| Urinalysis - Urine Glucose ≥1 | 3 | 6 |
| Urinalysis - Urine Ketones (Scalar) ≥1 | 0 | 2 |
| Urinalysis - Urine Protein ≥1 | 0 | 1 |
| Urinalysis - Urine Hemoglobin (Scalar) ≥1 | 1 | 3 |
| Urinalysis - Urine Urobilinogen ≥1 | 0 | 2 |
| Urinalysis - Urine Nitrite (Scalar) ≥1 | 0 | 1 |
| Urinalysis - Urine Leukocyte Esterase (Scalar) ≥1 | 0 | 2 |
AUC24 was measured on Day 21, 35, and 56 for dose 40 mg BID, 80 mg BID, and 120 mg BID, respectively. The planned analysis was not considered reliable by the sponsor.
| ng*hr/mL | PF-06882961 40 mg BID | PF-06882961 80 mg BID | PF-06882961 120 mg BID |
|---|---|---|---|
| AUC24 of PF-06882961 in Participants Received 40 mg BID, 80 mg BID, and 120 mg BID PF-06882961 | 1446 ± 236 | 1012 ± 1414 | 984.9 ± 2327 |
Cmax,ss was measured on Day 21, 35, and 56 for dose 40 mg BID, 80 mg BID, and 120 mg BID, respectively. The planned analysis was not considered reliable by the sponsor.
| ng/mL | PF-06882961 40 mg BID | PF-06882961 80 mg BID | PF-06882961 120 mg BID |
|---|---|---|---|
| Maximum Observed Concentration, Steady State (Cmax,ss) of PF-06882961 in Participants Received 40 mg BID, 80 mg BID, and 120 mg BID PF-06882961 | 150.3 ± 176 | 98.92 ± 1059 | 110.5 ± 3069 |
Collected over Baseline up to 35 days after last dose (Day 91). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/5 (0%) | 0/5 (0%) | 5/5 (100%) |
| PF-06882961 BID | 0/15 (0%) | 0/15 (0%) | 14/15 (93.3%) |
| Event | Placebo | PF-06882961 BID |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 3/5 | 12/15 |
| NauseaGastrointestinal disorders | 3/5 | 12/15 |
| VomitingGastrointestinal disorders | 1/5 | 12/15 |
| Decreased appetiteMetabolism and nutrition disorders | 1/5 | 9/15 |
| Upper respiratory tract infectionInfections and infestations | 2/5 | 1/15 |
| DizzinessNervous system disorders | 2/5 | 2/15 |
| HeadacheNervous system disorders | 2/5 | 4/15 |
| LeukocytosisBlood and lymphatic system disorders | 1/5 | 0/15 |
| PalpitationsCardiac disorders | 1/5 | 2/15 |
| Hepatic enzyme increasedInvestigations | 1/5 | 0/15 |
All enrolled participants who were randomized and received at least one dose of study treatment.
| Age, Continuous(Years) | Placebo | PF-06882961 BID | Total |
|---|---|---|---|
| Mean (SD) | 50 ± 4.64 | 49.5 ± 7.22 | 49.6 ± 6.56 |
| Age, Customized(Participants) | Placebo | PF-06882961 BID | Total |
|---|---|---|---|
| 20-44 Years | 1 | 4 | 5 |
| 45-60 Years | 4 | 11 | 15 |
| Sex: Female, Male(Participants) | Placebo | PF-06882961 BID | Total |
|---|---|---|---|
| Female | 1 | 8 | 9 |
| Male | 4 | 7 | 11 |
| Race/Ethnicity, Customized(Participants) | Placebo | PF-06882961 BID | Total |
|---|---|---|---|
| Asian | 5 | 15 | 20 |
| Race/Ethnicity, Customized(Participants) | Placebo | PF-06882961 BID | Total |
|---|---|---|---|
| Not Hispanic or Latino | 5 | 15 | 20 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Ran from Jul 2021 to primary completion in Feb 2022, 7 months.
Results were first posted in Oct 2024, 2 years 7 months after primary completion.
Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 7 months is above that.
Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Danuglipron